Quick Facts: Uses of Спазмалгон

• Addresses: Symptoms related to spasms of smooth muscles in internal organs.
• Contexts: May be used to manage discomfort associated with biliary tract conditions, gastrointestinal spasms, and urinary tract issues.
• Therapeutic Focus: Assists in the symptomatic management of mild to moderate pain originating from smooth muscle contractions.

Спазмалгон is a combination medication containing Metamizole, Pitofenone, and Fenpiverinium. It is indicated for the symptomatic management of discomfort arising from spasms of the smooth muscles in various internal organs. The medication is used to help relieve the mild to moderately expressed pain associated with conditions like colic of the stomach and intestine, spasms linked to gallstone disease, and disturbances in the urinary tract, such as kidney stone disease.

Its therapeutic domains include addressing painful menstruation (dysmenorrhea) and spasms related to the biliary tract. The use of this combination product aims to provide relief from the type of pain that responds to both analgesic and smooth-muscle-relaxing effects. Usage should align with recognized and established indications.

The eligibility for Спазмалгон (a medicine containing metamizole) is strictly defined by regulatory health authorities and includes absolute contraindications related to patient history, current health status, and life stage.

Populations Who Must Not Use Спазмалгон (Contraindicated)

• Hypersensitivity: Patients with known allergy to metamizole, other pyrazolones, or any excipients.
• Blood Conditions: Individuals with a history of metamizole-induced agranulocytosis (a severe drop in white blood cells) or other forms of severely impaired haematopoiesis.
• Metabolic Disorders: Patients with acute intermittent hepatic porphyria or Glucose-6-phosphate dehydrogenase (G6PD) deficiency.
• Pregnancy & Lactation: Use is absolutely contraindicated during the third trimester of pregnancy due to risks to the fetus. It is also generally contraindicated during breastfeeding as metabolites pass into milk.
• Age: Infants under 3 months of age or weighing less than 5 kg are contraindicated for use.

Restricted or Conditional Use

• Organ Function: Caution and potential dose reduction are required for patients with pre-existing impaired hepatic or renal function.
• Circulation: Special consideration is necessary for patients with arterial hypotension (low blood pressure) or an unstable circulatory state.

The interaction profile of Спазмалгон is primarily governed by the systemic effects of its component, Metamizole Sodium. This structure is defined by key pharmacokinetic (PK) and pharmacodynamic (PD) interactions documented in official regulatory materials.

Interaction Entity Map (High-Level)	Details Based on Regulatory Documentation
Pharmacokinetic Interactions (CYP Modulation)	Metamizole is documented as an inducer of hepatic enzymes, including CYP3A4, CYP2B6, and CYP2C19.
Exposure-Modifying Substances	This enzyme induction reduces the plasma concentrations and potential clinical effectiveness of co-administered CYP substrates, including Cyclosporine, Tacrolimus, Bupropion, Methadone, Valproate, and Sertraline.
Pharmacodynamic Interactions	Metamizole interferes with the antiplatelet effect of low-dose Acetylsalicylic acid (ASA). Co-administration with Chlorpromazine carries a documented risk of additive hypothermia.
Mandatory Restrictions & Requirements	Use is formally contraindicated during the third trimester of pregnancy due to risks of fetal renal and circulatory effects. Co-administration with intravenous Dihydralazine must be strictly avoided due to chemical incompatibility.
Monitoring Requirement	The interaction with immunosuppressants like Cyclosporine and Tacrolimus necessitates the mandatory monitoring of their serum concentrations to manage the reduced exposure effect.
Symptom Masking	Regulatory caution notes that co-use with antibiotics may mask the initial symptoms of agranulocytosis.

The regulatory basis for this profile establishes that the CYP induction mechanism leads to required procedural constraints, such as drug level monitoring, for many co-administered medicines, alongside several formally prohibited combinations clearly defined in the product labeling.

Спазмалгон is a fixed-dose combination containing three pharmacological agents: metamizole, pitofenone, and fenpiverinium bromide. The overall mechanism involves a combined action on prostaglandin synthesis, smooth muscle contractility, and cholinergic signaling.

Metamizole, primarily through its active metabolites like 4-methyl-amino-antipyrine (MAA), acts as an inhibitor of central cyclooxygenase-3 (COX-3), and exhibits antagonism against prostaglandin E2 (PGE2)-induced signaling. Its metabolite, 4-amino-antipyrine (AA), may also function as an agonist at the central cannabinoid receptor type 1 ( CB1). Additionally, metamizole has been associated with reduced intracellular Ca^2+ release by inhibiting the synthesis of inositol phosphate, modulating smooth muscle tone.

Pitofenone is a direct smooth muscle antispasmodic agent that inhibits muscle contraction by blocking voltage-dependent Ca^2+ channels in the smooth muscle cell membrane. This action decreases the intracellular Ca^2+ concentration, thereby modulating the contractile state of the tissue. Fenpiverinium bromide acts as a muscarinic acetylcholine receptor antagonist (anticholinergic), inhibiting nerve-mediated contraction of smooth muscles. This results in the systemic physiological consequence of reduced smooth muscle contractility in the visceral organs.

Official Administration Guidelines

Спазмалгон (Metamizole, Pitofenone, and Fenpiverinium Bromide) is intended for short-term use only, typically administered for acute episodes. The administration route and dosing regimen are determined by the formulation and the severity of the condition.

---

Dosing and Route of Administration

The medicine is available in two main official routes: oral for tablets and parenteral (intravenous (IV) or intramuscular (IM)) for the solution for injection. Oral administration generally follows a schedule where a single dose is taken up to four times daily.

Administration Scope	Official Requirement
Standard Oral Dose (Adult ge 15 years)	Up to 1,000 mg Metamizole equivalent per single dose. Maximum daily dose is limited to 4,000 mg Metamizole.
Parenteral Dose (IV/IM)	A single parenteral dose can be up to 1,000 mg Metamizole equivalent. The total daily dose must not exceed 5,000 mg.
Frequency and Interval	Dosing must not exceed four times per day, with a mandatory minimum interval of 6 to 8 hours between administrations.

---

Procedural and Population-Specific Rules

Intravenous administration must be performed very slowly, typically over three to five minutes, and must be conducted under medical supervision. Tablets are taken whole with water, sometimes specified as after eating. If a dose is missed, the next scheduled dose should be taken at the regular time; doubling the next dose is not permitted.

For specific populations, dose adjustment is required. The dose is reduced for older adults and patients with impaired renal or hepatic function due to potential delays in the excretion of the active metabolites. Dosing for younger patients is determined based on body weight.

Research Evidence / Overview of Studies for Спазмалгон

---

Evidence for Use in Symptomatic Pain Treatment

The research available for this drug combination includes short-term Randomized Controlled Trials (RCTs) and other comparative studies. These trials were primarily used in research exploring how symptoms change over time and were applied in studies examining patient-reported experiences of acute physical discomfort. Researchers focused on populations of adults who experienced conditions associated with acute or disruptive episodes of pain, such as intestinal, renal, or biliary colic.

The studies monitored outcomes related to physical discomfort, primarily through standardized scales to measure investigating changes in pain intensity over time. The findings describe patterns observed in the studies where measurements of symptom change were reported over the hours following administration. This evidence provides insight into short-term changes in acute settings.

Evidence for Use in Smooth Muscle Spasm Relief

Research has explored the use of this combination in settings where outcomes related to systemic or functional imbalance, specifically smooth muscle spasms, were the primary focus. This involved comparative clinical trials and pharmacological studies used in research contexts involving fluctuating or unstable symptoms tied to the digestive or urinary tracts. The studies monitored outcomes capturing phases of heightened symptom activity, such as the reported changes in spasm frequency and duration.

Studies reported measurements of changes in spasm symptoms during the observed time intervals. The research describes patterns where the documented the timing of reported changes in spasm symptoms was observed in some studies shortly after the combination was administered.

---

️ Long-Term Studies and Follow-Up Data

Research primarily focuses on the acute and short-term resolution of symptoms, meaning the follow-up durations were limited in most available studies. Evidence describing how symptoms change over extended time intervals—for example, over several months—is limited.

The durability of any observed response has not been fully established because studies typically do not track patients long enough to assess this outcome. Therefore, the long-term effects of this combination are an area where data are still emerging, and certainty regarding sustained patterns of relief remains low.

---

What Is Still Uncertain About Спазмалгон Research

A number of aspects related to the drug combination remain areas of ongoing research and uncertainty. The comparative evidence is lacking for many potential indications. Long-term effects are not fully established, as most research was studied for only short, defined periods related to acute symptom episodes. The evidence quality varies across studies, with many relying on observational data rather than highly controlled trial designs. The overall findings describe group patterns, not personal outcomes.

Common questions about Спазмалгон (FAQ)

---

Q: How quickly does Спазмалгон usually start to work?

A: Official information on the main analgesic component suggests that the pain-relieving effect may typically begin within 30 minutes after taking the oral tablet.

Q: How long does the effect of one dose of Спазмалгон typically last?

A: The pain-relieving effects from a single dose of the active components may persist for approximately 4 hours. The specific instructions for the minimum time interval between doses are detailed in the full administration guidelines.

Q: Can taking Спазмалгон make you feel drowsy or sleepy?

A: The official product information mentions that dizziness and hypotension (low blood pressure) are known adverse effects. Product labeling advises that caution may be necessary when performing activities requiring mental alertness, due to the potential for impaired reactions.

Q: Is it okay to drive or operate machinery after taking Спазмалгон?

A: Due to potential effects like dizziness, the product information indicates that the ability to react or concentrate may be impaired. Caution is advised for activities such as driving or operating machinery.

Q: Can teenagers or children safely use Спазмалгон?

A: Official guidelines state the use is contraindicated for infants under 3 months of age or those weighing less than 5 kg. For older patients, specific administration is based on body weight or age and must follow authorized guidance.

Q: Are older adults more likely to experience side effects from Спазмалгон?

A: Official regulatory guidelines specify that a dose reduction may be required for older adults. This precaution is often in place due to potential delays in how the body processes and excretes the medicine’s active components.

Q: What should I do if I miss a dose of Спазмалгон?

A: Official administration guidelines state that if a dose is missed, patients are generally instructed to take the next scheduled dose at the regular time. Doubling the next dose to compensate for a missed one is not permitted.

Q: Is it normal to feel a dry mouth after taking Спазмалгон?

A: Dry mouth is a known side effect associated with the anticholinergic component (Fenpiverinium Bromide) in the medicine, which is a class of drugs that can influence the body's natural secretions.

Q: Why is it important to take Спазмалгон with a full glass of water?

A: Taking the tablets whole with water is standard procedure to help ensure proper drug dissolution and absorption, and may help prevent local irritation. Tablets are generally directed to be taken whole with water.

Q: Can I crush or chew the Спазмалгон tablets?

A: Official product instructions generally direct that the tablets be taken whole. This is necessary for the medicine to release its ingredients as intended and should be followed unless a healthcare professional advises otherwise.

Q: What is the risk of gastrointestinal upset with Спазмалгон?

A: The primary pain component, metamizole, is generally associated with a lower risk of severe gastrointestinal toxicity compared to traditional NSAIDs. However, minor gastrointestinal disorders, such as nausea or an upset stomach, may still occur.

Q: Can taking too much Спазмалгон cause confusion or restlessness?

A: The primary risks associated with an overdose involve hypotension (severely low blood pressure), though other central nervous system effects are possible. If an overdose is suspected, urgent medical assistance should be sought.

Q: Does using Спазмалгон affect the results of any common lab tests?

A: Official documents note that the medicine is known to interfere with some laboratory methods used to measure creatinine. This interference can potentially lead to inaccurate test results.

Q: Is it normal to see slightly reddish urine after taking high doses of Спазмалгон?

A: A reddish colouration of the urine may occur, particularly after high doses. Official documents note that this effect is due to a harmless metabolite of the drug and is not usually considered clinically significant.

Q: Can I take other pain relievers shortly after taking Спазмалгон?

A: Due to a known interaction, Спазмалгон should not be combined with low-dose Acetylsalicylic acid (ASA), as it can reduce ASA's antiplatelet effect. Consultation with a healthcare provider is required before combining it with any other pain relievers.

How to Store and Dispose of Спазмалгон

Official regulatory information for Спазмалгон tablets mandates specific environmental and temperature controls to maintain the product's stability and quality.

Storage Requirements

• Temperature Control: The tablets must be stored at a temperature that does not exceed 25 C.
• Environmental Protection: The medicine must be kept in its original container to provide necessary protection from light and moisture.
• Child Safety: It is a mandatory requirement to keep the product out of the sight and reach of children.

Disposal Instructions

Unused or expired Спазмалгон must be handled as pharmaceutical waste and not disposed of in household trash or wastewater. The product must be returned to a pharmacist or discarded according to specific local environmental requirements.